| UTHEALTH HOME ABOUT SBMI A-Z WEBMAIL INSIDE THE UNIVERSITY |
|
|||||||
|
Kinase Fusion Gene:STK10_XIAP |
Kinase Fusion Protein Summary |
 Kinase Fusion gene summary |
| Kinase Fusion partner gene information | Kinase Fusion gene name: STK10_XIAP | KinaseFusionDB ID: KFG6125 | FusionGDB2.0 ID: KFG6125 | Hgene | Tgene | Gene symbol | STK10 | XIAP | Gene ID | 6793 | 331 | |
| Gene name | serine/threonine kinase 10 | X-linked inhibitor of apoptosis | ||||||||||
| Synonyms | LOK|PRO2729 | API3|BIRC4|IAP-3|ILP1|MIHA|XLP2|hIAP-3|hIAP3 | ||||||||||
| Cytomap | 5q35.1 | Xq25 | ||||||||||
| Type of gene | protein-coding | protein-coding | ||||||||||
| Description | serine/threonine-protein kinase 10lymphocyte-oriented kinase | E3 ubiquitin-protein ligase XIAPIAP-like protein 1RING-type E3 ubiquitin transferase XIAPX-linked IAPX-linked inhibitor of apoptosis, E3 ubiquitin protein ligasebaculoviral IAP repeat-containing protein 4inhibitor of apoptosis protein 3 | ||||||||||
| Modification date | 20240305 | 20240407 | ||||||||||
| UniProtAcc | O94804 | P98170 | ||||||||||
| Ensembl transtripts involved in fusion gene | ENST ids | ENST00000176763, ENST00000517775, | ENST00000355640, ENST00000371199, ENST00000434753, ENST00000468691, | |||||||||
| Context (manual curation of fusion genes in KinaseFusionDB) | PubMed: STK10 [Title/Abstract] AND XIAP [Title/Abstract] AND fusion [Title/Abstract] | |||||||||||
| Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0) | STK10(171607186)-XIAP(122999413), # samples:1 STK10(171606716)-XIAP(122999320), # samples:1 | |||||||||||
| Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
| Partner | Gene | GO ID | GO term | PubMed ID |
| Hgene | STK10 | GO:0046777 | protein autophosphorylation | 12639966|18239682 |
| Tgene | XIAP | GO:0010804 | negative regulation of tumor necrosis factor-mediated signaling pathway | 11865055 |
| Tgene | XIAP | GO:0031398 | positive regulation of protein ubiquitination | 21931591 |
| Tgene | XIAP | GO:0032481 | positive regulation of type I interferon production | 36394357 |
| Tgene | XIAP | GO:0042742 | defense response to bacterium | 29452636 |
| Tgene | XIAP | GO:0042981 | regulation of apoptotic process | 11865055 |
| Tgene | XIAP | GO:0043066 | negative regulation of apoptotic process | 11257230 |
| Tgene | XIAP | GO:0043123 | positive regulation of canonical NF-kappaB signal transduction | 19667203|22607974 |
| Tgene | XIAP | GO:0043154 | negative regulation of cysteine-type endopeptidase activity involved in apoptotic process | 11583623 |
| Tgene | XIAP | GO:0046330 | positive regulation of JNK cascade | 11865055 |
| Tgene | XIAP | GO:0070427 | nucleotide-binding oligomerization domain containing 1 signaling pathway | 29452636 |
| Tgene | XIAP | GO:0070431 | nucleotide-binding oligomerization domain containing 2 signaling pathway | 19667203|22607974|29452636 |
| Tgene | XIAP | GO:0070534 | protein K63-linked ubiquitination | 29452636 |
| Tgene | XIAP | GO:0097340 | inhibition of cysteine-type endopeptidase activity | 11865055 |
| Tgene | XIAP | GO:1902530 | positive regulation of protein linear polyubiquitination | 21931591|22607974 |
| Kinase Fusion gene breakpoints across STK10 (5'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
| Kinase Fusion gene breakpoints across XIAP (3'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
Top |
Kinase Fusion Gene Sample Information |
| Kinase Fusion gene information. |
| Kinase Fusion gene information from four resources (ChiTars 5.0, ChimerDB 4.0, COSMIC, and CCLE) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| Source | Sample | Hgene | Hchr | Hbp | Tgene | Tchr | Tbp |
| ChiTaRS5.0 | BM930492 | STK10 | chr5 | 171607186 | XIAP | chrX | 122999413 |
| ChiTaRS5.0 | BQ187681 | STK10 | chr5 | 171606716 | XIAP | chrX | 122999320 |
Top |
Kinase Fusion ORF Analysis |
| Kinase Fusion information from ORFfinder translation from full-length transcript sequence from KinaseFusionDB. |
| Henst | Tenst | Hgene | Hchr | Hbp | Tgene | Tchr | Tbp | Seq length (transcript) | Seq length (amino acids) |
Top |
Kinase Fusion Amino Acid Sequences |
| For individual full-length fusion transcript sequence from KinaseFusionDB, we ran ORFfinder and chose the longest ORF among the all predicted ones. |
| >Henst_Tenst_Hgene_Hchr_Hbp_Tgene_Tchr_Tbp_length(fusion AA)_AAseq |
Multiple Sequence Alignment of All Fusion Protein Isoforms |
Top |
Kinase Fusion Protein Functional Features |
| Four levels of functional features of fusion genes Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/:171607186/:122999413) - FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels. - How to search 1. Put your fusion gene symbol. 2. Press the tab key until there will be shown the breakpoint information filled. 4. Go down and press 'Search' tab twice. 4. Go down to have the hyperlink of the search result. 5. Click the hyperlink. 6. See the FGviewer result for your fusion gene. |
 |
| Main function of each fusion partner protein. (from UniProt) |
| Hgene | Tgene |
| STK10 | XIAP |
| FUNCTION: Serine/threonine-protein kinase involved in regulation of lymphocyte migration. Phosphorylates MSN, and possibly PLK1. Involved in regulation of lymphocyte migration by mediating phosphorylation of ERM proteins such as MSN. Acts as a negative regulator of MAP3K1/MEKK1. May also act as a cell cycle regulator by acting as a polo kinase kinase: mediates phosphorylation of PLK1 in vitro; however such data require additional evidences in vivo. {ECO:0000269|PubMed:11903060, ECO:0000269|PubMed:12639966, ECO:0000269|PubMed:19255442}. | FUNCTION: Multi-functional protein which regulates not only caspases and apoptosis, but also modulates inflammatory signaling and immunity, copper homeostasis, mitogenic kinase signaling, cell proliferation, as well as cell invasion and metastasis (PubMed:11447297, PubMed:12121969, PubMed:9230442, PubMed:11257230, PubMed:11257231, PubMed:12620238, PubMed:17967870, PubMed:19473982, PubMed:20154138, PubMed:22103349, PubMed:17560374). Acts as a direct caspase inhibitor (PubMed:11257230, PubMed:11257231, PubMed:12620238). Directly bind to the active site pocket of CASP3 and CASP7 and obstructs substrate entry (PubMed:11257230, PubMed:11257231, PubMed:16352606, PubMed:16916640). Inactivates CASP9 by keeping it in a monomeric, inactive state (PubMed:12620238). Acts as an E3 ubiquitin-protein ligase regulating NF-kappa-B signaling and the target proteins for its E3 ubiquitin-protein ligase activity include: RIPK1, RIPK2, MAP3K2/MEKK2, DIABLO/SMAC, AIFM1, CCS, PTEN and BIRC5/survivin (PubMed:17967870, PubMed:19473982, PubMed:20154138, PubMed:22103349, PubMed:22607974, PubMed:30026309, PubMed:29452636, PubMed:17560374). Acts as an important regulator of innate immunity by mediating 'Lys-63'-linked polyubiquitination of RIPK2 downstream of NOD1 and NOD2, thereby transforming RIPK2 into a scaffolding protein for downstream effectors, ultimately leading to activation of the NF-kappa-B and MAP kinases signaling (PubMed:19667203, PubMed:22607974, PubMed:30026309, PubMed:29452636). 'Lys-63'-linked polyubiquitination of RIPK2 also promotes recruitment of the LUBAC complex to RIPK2 (PubMed:22607974, PubMed:29452636). Regulates the BMP signaling pathway and the SMAD and MAP3K7/TAK1 dependent pathways leading to NF-kappa-B and JNK activation (PubMed:17560374). Ubiquitination of CCS leads to enhancement of its chaperone activity toward its physiologic target, SOD1, rather than proteasomal degradation (PubMed:20154138). Ubiquitination of MAP3K2/MEKK2 and AIFM1 does not lead to proteasomal degradation (PubMed:17967870, PubMed:22103349). Plays a role in copper homeostasis by ubiquitinating COMMD1 and promoting its proteasomal degradation (PubMed:14685266). Can also function as E3 ubiquitin-protein ligase of the NEDD8 conjugation pathway, targeting effector caspases for neddylation and inactivation (PubMed:21145488). Ubiquitinates and therefore mediates the proteasomal degradation of BCL2 in response to apoptosis (PubMed:29020630). Protects cells from spontaneous formation of the ripoptosome, a large multi-protein complex that has the capability to kill cancer cells in a caspase-dependent and caspase-independent manner (PubMed:22095281). Suppresses ripoptosome formation by ubiquitinating RIPK1 and CASP8 (PubMed:22095281). Acts as a positive regulator of Wnt signaling and ubiquitinates TLE1, TLE2, TLE3, TLE4 and AES (PubMed:22304967). Ubiquitination of TLE3 results in inhibition of its interaction with TCF7L2/TCF4 thereby allowing efficient recruitment and binding of the transcriptional coactivator beta-catenin to TCF7L2/TCF4 that is required to initiate a Wnt-specific transcriptional program (PubMed:22304967). {ECO:0000269|PubMed:11257230, ECO:0000269|PubMed:11257231, ECO:0000269|PubMed:11447297, ECO:0000269|PubMed:12121969, ECO:0000269|PubMed:12620238, ECO:0000269|PubMed:14685266, ECO:0000269|PubMed:16352606, ECO:0000269|PubMed:16916640, ECO:0000269|PubMed:17560374, ECO:0000269|PubMed:17967870, ECO:0000269|PubMed:19473982, ECO:0000269|PubMed:19667203, ECO:0000269|PubMed:20154138, ECO:0000269|PubMed:21145488, ECO:0000269|PubMed:22103349, ECO:0000269|PubMed:22304967, ECO:0000269|PubMed:22607974, ECO:0000269|PubMed:29020630, ECO:0000269|PubMed:29452636, ECO:0000269|PubMed:30026309, ECO:0000269|PubMed:9230442, ECO:0000303|PubMed:22095281}. |
| Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at * Minus value of BPloci means that the break pointn is located before the CDS. |
| - Retained domain in the 5'-partner of fusion protein (protein functional feature from UniProt). |
| Partner | Hgeneene | Hbp | Tgeneene | Tbp | ENST | BPexon | TotalExon | Protein feature loci | BPloci | TotalLen | Feature | Note |
| - Retained domain in the 3'-partner of fusion protein (protein functional feature from UniProt). |
| Partner | Hgeneene | Hbp | Tgeneene | Tbp | ENST | BPexon | TotalExon | Protein feature loci | BPloci | TotalLen | Feature | Note |
Top |
Kinase-Substrate Information of STK10_XIAP |
| Phosphorylation target of the kinase (phosphosite, 03-17-2024) |
| Kinase | Kinase UniProt Acc | Kinase species | Substrate | Substrate UniProt Acc | Substrate phosphorylated residues | Substrate phosphorylated sites (+/-7AA) | Domain |
| STK10 | O94804 | human | RDX | P35241 | T564 | AGRDKyKtLRQIRQG | ERM_C |
| STK10 | O94804 | human | EZR | P15311 | T567 | QGRDkyKtLRQIRQG | ERM_C |
| STK10 | O94804 | human | PLK1 | P53350 | T210 | YDGERKktLCGtPNy | Pkinase |
| STK10 | O94804 | human | MSN | P26038 | T558 | LGRDKyKtLRQIRQG | ERM_C |
| Biological Network Integration of This Kinase and Substrates (GeneMANIA website) |
| Enriched GO biological processes of the phosphorylation target genes of the kinase |
| Kinase | GOID | GO term | P.adjust |
| STK10 | ID | Description | 0.00e+00 |
| STK10 | GO:1902946 | protein localization to early endosome | 1.25e-07 |
| STK10 | GO:1905668 | positive regulation of protein localization to endosome | 1.25e-07 |
| STK10 | GO:1905666 | regulation of protein localization to endosome | 1.25e-07 |
| STK10 | GO:1903651 | positive regulation of cytoplasmic transport | 1.49e-07 |
| STK10 | GO:2000641 | regulation of early endosome to late endosome transport | 2.54e-07 |
| STK10 | GO:0036010 | protein localization to endosome | 6.39e-07 |
| STK10 | GO:0045732 | positive regulation of protein catabolic process | 7.22e-07 |
| STK10 | GO:1902115 | regulation of organelle assembly | 7.22e-07 |
| STK10 | GO:1903649 | regulation of cytoplasmic transport | 7.22e-07 |
| STK10 | GO:0045022 | early endosome to late endosome transport | 1.73e-06 |
| STK10 | GO:0061028 | establishment of endothelial barrier | 2.01e-06 |
| STK10 | GO:0098927 | vesicle-mediated transport between endosomal compartments | 2.01e-06 |
| STK10 | GO:0042176 | regulation of protein catabolic process | 3.85e-06 |
| STK10 | GO:0001885 | endothelial cell development | 3.89e-06 |
| STK10 | GO:1903829 | positive regulation of protein localization | 9.79e-06 |
| STK10 | GO:0045446 | endothelial cell differentiation | 2.53e-05 |
| STK10 | GO:0008360 | regulation of cell shape | 3.43e-05 |
| STK10 | GO:0003158 | endothelium development | 3.46e-05 |
| STK10 | GO:0072697 | protein localization to cell cortex | 3.58e-05 |
| STK10 | GO:0016482 | cytosolic transport | 6.43e-05 |
| STK10 | GO:0032388 | positive regulation of intracellular transport | 8.26e-05 |
| STK10 | GO:0002064 | epithelial cell development | 9.52e-05 |
| STK10 | GO:0022604 | regulation of cell morphogenesis | 1.40e-04 |
| STK10 | GO:0032386 | regulation of intracellular transport | 3.38e-04 |
| STK10 | GO:0010737 | protein kinase A signaling | 3.47e-04 |
| STK10 | GO:1990778 | protein localization to cell periphery | 3.61e-04 |
| STK10 | GO:0032535 | regulation of cellular component size | 4.01e-04 |
| STK10 | GO:0140694 | non-membrane-bounded organelle assembly | 5.18e-04 |
| STK10 | GO:0022406 | membrane docking | 1.77e-03 |
| STK10 | GO:1904375 | regulation of protein localization to cell periphery | 3.80e-03 |
| STK10 | GO:0030010 | establishment of cell polarity | 4.77e-03 |
| STK10 | GO:0051017 | actin filament bundle assembly | 4.92e-03 |
| STK10 | GO:0061572 | actin filament bundle organization | 5.01e-03 |
| STK10 | GO:0008361 | regulation of cell size | 6.24e-03 |
| STK10 | GO:0007051 | spindle organization | 7.07e-03 |
| STK10 | GO:0007163 | establishment or maintenance of cell polarity | 8.75e-03 |
| STK10 | GO:0072659 | protein localization to plasma membrane | 1.37e-02 |
| STK10 | GO:1901990 | regulation of mitotic cell cycle phase transition | 1.84e-02 |
| STK10 | GO:0030953 | astral microtubule organization | 1.84e-02 |
| STK10 | GO:0051081 | nuclear membrane disassembly | 1.84e-02 |
| STK10 | GO:0051660 | establishment of centrosome localization | 1.84e-02 |
| STK10 | GO:0071803 | positive regulation of podosome assembly | 1.84e-02 |
| STK10 | GO:0010639 | negative regulation of organelle organization | 1.84e-02 |
| STK10 | GO:0030397 | membrane disassembly | 1.94e-02 |
| STK10 | GO:0034111 | negative regulation of homotypic cell-cell adhesion | 1.97e-02 |
| STK10 | GO:0071394 | cellular response to testosterone stimulus | 1.97e-02 |
| STK10 | GO:0032530 | regulation of microvillus organization | 1.97e-02 |
| STK10 | GO:0032536 | regulation of cell projection size | 1.97e-02 |
| STK10 | GO:0070486 | leukocyte aggregation | 1.97e-02 |
Top |
Related Drugs to STK10_XIAP |
| Drugs used for this fusion-positive patient. (Manual curation of PubMed, 04-30-2022 + MyCancerGenome) |
| Hgene | Tgene | Drug | Source | PMID |
| Distribution of the number of studies mentioning STK10-XIAP and kinase inhibitors the PubMed Abstract (04-01-2024) |
| Fusion gene - drug pair 1 | Fusion gene - drug pair 2 | PMID | Publication date | DOI | Study title |
Top |
Related Diseases to STK10_XIAP |
| Diseases that have this fusion gene. (Manual curation of PubMed, 04-30-2022 + MyCancerGenome) |
| Hgene | Tgene | Disease | Source | PMID |
| Related diseases from the literature mentioned this fusion gene and drug. (PubMed, 04-01-2024) |
| MeSH ID | MeSH term |
| Diseases associated with fusion partners. (DisGeNet 4.0) |
| Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
Top |
Clinical Trials of the Found Drugs/Small Molecules |
| Statistics of the Clinical Trials of the Found Kinase Inibitors from clinicaltrials.gov (06-17-2024) |
| Clinical Trials from clinicaltrials.gov (06-17-2024) |
| Fusion Gene | Kinase Inhibitor | NCT ID | Study Status | Phases | Disease | # Enrolment | Date |
Copyright 2024-Present -The University of Texas Health Science Center at Houston
Web File Viewing | Emergency Information |Campus Carry|Site Policies |